These data clearly demonstrate that miR-155 plays an important role in ccRCC tumorigenesis and progression by negative regulation of its target E2F2; thus, miR-155 may be a potential therapeutic target for ccRCC treatment. The gene discussed is E2F2; the disease is nonpapillary renal cell carcinoma.